Effectiveness of deferiprone in transfusionindependent beta-thalassemia/HbE patients

Hematology

Volumn 16, Issue 2, 2011, Pages 113-122

  Akrawinthawong, Krittapoom ^a   Chaowalit, Nithima ^a   Chatuparisuth, Thanasaporn ^a   Siritanaratkul, Noppadol ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Deferiprone; Oxidative stress; Sole iron chelator; Thalassemia intermedia

Indexed keywords

ADRENALIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DEFERIPRONE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; GLUCOSE; HEMOGLOBIN; MALONALDEHYDE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSFERRIN; UREA; HEMOGLOBIN E; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADULT; AGRANULOCYTOSIS; ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; HEMATOLOGY; HUMAN; IRON OVERLOAD; LEUKOCYTE COUNT; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MACULOPAPULAR RASH; MALE; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SKIN DISEASE; THORAX PAIN; THROMBOCYTE COUNT; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; ADOLESCENT; BLOOD; CARDIOVASCULAR MALFORMATION; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; FOLLOW UP; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR ABNORMALITIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HEMOGLOBIN E; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; OXIDATIVE STRESS; PYRIDONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952658675     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X12940641877768     Document Type: Article

References (56)

1. Viprakasit V, Lee-Lee C, Chong QT, Lin KH, Khuhapinant A. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009;90:435-45.
2. Fucharoen S, Ketvichit P, Pootrakul P, Siritanaratkul N, Piankijagum A, Wasi P. Clinical manifestation of beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol 2000;22:552-7.
3. Nuntakarn L, Fucharoen S, Fucharoen G, Sanchaisuriya K, Jetsrisuparb A, Wiangnon S. Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E-beta-thalassemia in Northeast Thailand. Blood Cells Mol Dis 2009;42:32-5.
4. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107:3436-41.
5. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol 2009;147:634-40.
6. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97:3411-6.
7. Cappellini MD, Pattoneri P. Oral iron chelators. Annu Rev Med 2009;60:25-38.
8. Cianciulli P. Treatment of iron overload in thalassemia. Pediatr Endocrinol Rev 2008;6(Suppl 1):208-13.
9. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007;47:1919-29. (Pubitemid 47438560)
10. Taher A, Chamoun FM, Koussa S, Saad MA, Khoriaty AI, Neeman R, et al. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol 1999;101:173-7.
11. Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin 2008;32:49-62.
12. Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. Hemoglobin 2006;30:229-38.
13. Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 2008;141:882-90. (Pubitemid 351724860)
14. Vlachaki E, Tselios K, Perifanis V, Tsatra I, Tsayas I. Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature. Clin Rheumatol 2008;27:1459-61.
15. Kwiatkowski JL. Oral iron chelators. Pediatr Clin North Am 2008;55:461-482, x.
16. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553-84. (Pubitemid 36724096)
17. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008;32:1-15. (Pubitemid 351264512)
18. Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E. Recent developments in iron chelation therapy. Klin Padiatr 2007;219:158-65. (Pubitemid 46983779)
19. Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann NY Acad Sci 2005;1054:175-82. (Pubitemid 43031022)
20. Victor Hoffbrand A. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005;18:299-317.
21. Olivieri NF, Brittenham GM,Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995;332:918-22.
22. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23. (Pubitemid 28377682)
23. Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300. (Pubitemid 28018757)
24. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305-10. (Pubitemid 36859618)
25. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004;104:263-9. (Pubitemid 38879867)
26. Arques S, Roux E, Luccioni R. Current clinical applications of spectral tissue Doppler echocardiography (E/E9 ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function. Cardiovasc Ultrasound 2007;5:16.
27. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523-30. (Pubitemid 46218775)
28. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 2007;92:658-65. (Pubitemid 350144268)
29. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94.
30. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta 2010;1800:760-9.
31. Taher A, El Rassi F, Isma'eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008;93:1584-6.
32. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8. (Pubitemid 24265699)
33. Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S, et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 2009;146:569-72.
34. Domenica Cappellini M, Tavazzi D, Duca L, Marelli S, Fiorelli G. Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia. Transfus Sci 2000;23:245-6.
35. Al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol 1992;82:431-6.
36. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-87. (Pubitemid 40298370)
37. Piga A, Longo F,Duca L,Roggero S, Vinciguerra T, Calabrese R, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009;84:29-33.
38. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 2000;95:2975-82. (Pubitemid 30235912)
39. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670-7. (Pubitemid 37193611)
40. Hill GE, Miller JA, Baxter BT, Klassen LW, Duryee MJ, Tuma DJ, et al. Association of malondialdehyde-acetaldehyde (MAA) adducted proteins with atherosclerotic-induced vascular inflammatory injury. Atherosclerosis 1998;141:107-16. (Pubitemid 28539421)
41. Chuang CH, Huang CE, Chen HL. DNA strand breakage and lipid peroxidation after exposure to welding fumes in vivo. Mutagenesis 2010;25:71-6.
42. Willis MS, Klassen LW, Tuma DJ, Thiele GM. Malondialdehyde-acetaldehyde- haptenated protein induces cell death by induction of necrosis and apoptosis in immune cells. Int Immunopharmacol 2002;2:519-35. (Pubitemid 34169747)
43. Linpisarn S, Satoh K, Mikami T, Orimo H, Shinjo S, Yoshino Y. Effects of iron on lipid peroxidation. Int J Hematol 1991;54:181-8.
44. Fucharoen S, Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr Opin Hematol 2000;7:106-12. (Pubitemid 30106542)
45. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101. (Pubitemid 47517510)
46. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008;8:620-32.
47. Bosi G, Crepaz R, Gamberini MR, Fortini M, Scarcia S, Bonsante E, et al. Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart 2003;89:762-6. (Pubitemid 36760638)
48. Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990;82:88-94. (Pubitemid 20216319)
49. Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 1993;88:1127-35. (Pubitemid 23264030)
50. Isma'eel H, Chafic AH, Rassi FE, Inati A, Koussa S, Daher R, et al. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol 2008;102:363-7.
51. Leon MB, Borer JS, Bacharach SL, Green MV, Benz EJ Jr, Griffith P, et al Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. N Engl J Med 1979;301:1143-8. (Pubitemid 10158785)
52. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971;51:209-21.
53. Aessopos A, Farmakis D. Pulmonary hypertension in betathalassemia. Ann NY Acad Sci 2005;1054:342-9.
54. Grubina R, Huang Z, Shiva S, Joshi MS, Azarov I, Basu S, et al. Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy- and oxyhemoglobin. J Biol Chem 2007;282:12916-27. (Pubitemid 47100601)
55. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007;110:2166-72. (Pubitemid 47443936)
56. Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed) 2009;1:161-78.